Journal article
Feasibility of Multi-Institutional Data Collection for Medication Prior Authorization in Pediatric Oncology
JCO oncology practice, Vol.21(7), pp.1017-1023
07/2025
DOI: 10.1200/OP-24-00794
PMID: 39889257
Abstract
Medication prior authorization (mPA) occurs commonly in US cancer care. While medical oncologists report potential harm resulting from this requirement, the impact of mPA in pediatric oncology is unknown. This study's primary aim was to test the feasibility of prospectively collecting multi-institutional data on mPA in pediatric oncology, while secondarily assessing for resultant delays in care.
Pediatric patients with cancer were enrolled between September 2021 and December 2022 at three Children's Oncology Group institutions participating in the National Cancer Institute Community Oncology Research Program. Data collected for each mPA event included the name of the medication, indication, desired initiation date, and actual date administered.
Among 68 patients enrolled at three institutions, 38 (56%) were subject to at least one mPA. A total of 69 mPAs occurred in these 38 patients, with 36 (52%) for supportive care and 33 (48%) for treatment medications. Ultimately, 61 of 69 (88%) mPAs were approved as prescribed (33 of 33 treatment mPAs) with a range of 5-240 minutes of provider/staff time required to resolve. MPAs delayed care in 15 of 69 (22%) cases with a range of 1-21 days. Most providers reported minimal or no additional burden to characterizing mPA data.
Despite the complexity and variability of institutional mPA processes, it is feasible to prospectively collect multi-institutional mPA data. No cancer treatment mPA request led to alterations in prescriptions. Delays in care because of mPA affect roughly one quarter of pediatric patients with cancer, the consequences of which remain unknown.
Details
- Title: Subtitle
- Feasibility of Multi-Institutional Data Collection for Medication Prior Authorization in Pediatric Oncology
- Creators
- David S Dickens - University of Iowa Hospitals and ClinicsKathryn Juhl - Blank Children's HospitalPeggy Bennett - Helen DeVos Children's HospitalMegan Sullivan - Helen DeVos Children's HospitalAnn Mancuso - Prisma HealthSusan K Parsons - Tufts Medical CenterBrad H Pollock - University of California, Davis
- Resource Type
- Journal article
- Publication Details
- JCO oncology practice, Vol.21(7), pp.1017-1023
- DOI
- 10.1200/OP-24-00794
- PMID
- 39889257
- NLM abbreviation
- JCO Oncol Pract
- ISSN
- 2688-1535
- eISSN
- 2688-1535
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Grant note
- National Cancer Institute: UG1 CA189955 NCATS: UL1 TR001860
Supported in part by National Cancer Institute UG1 CA189955 and NCATS UL1 TR001860.
- Language
- English
- Electronic publication date
- 01/31/2025
- Date published
- 07/2025
- Academic Unit
- Stead Family Department of Pediatrics; Hematology/Oncology
- Record Identifier
- 9984781278202771
Metrics
7 Record Views